Scholarlink

<p>Chronic hand eczema (CHE) is a prevalent inflammatory skin condition affecting the hands, characterized by eczematous lesions, causing severe itching and discomfort. Drugs targeting the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway have emerged as new potential treatment for CHE. In this systematic review and meta-analysis, we aimed to assess the efficacy and safety of delgocitinib in CHE patients. We conducted a comprehensive search across available electronic databases to identify eligible studies reported up to January 2025. Outcomes were reported as risk ratios (RR), mean difference (MD), and confidence intervals (CIs), using RevMan 5.4. A P-value ≤ 0.05 is considered statistically significant. Three studies reporting on 1062 patients were included. The pooled analysis of the Hand Eczema Severity Index (HECSI) Score at Week 16 showed a significantly greater reduction in the delgocitinib 20 mg/g group (MD= − 39.65; 95% CI: − 47.22 to − 32.08; I² = 14%). There was no significant difference in overall adverse events between the groups. The discontinuation rate due to adverse events was lower in patients in the delgocitinib group. Delgocitinib significantly improved the CHE status, with no notable incidence of adverse events. Futures trials are recommended, including a wider population and longer follow-up durations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of delgocitinib in the treatment of chronic hand eczema: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年2月28日

查看全文
  • Abdelaziz A. Awad,
  • Basma M. El-Khalifa,
  • Esraa Awad,
  • Youssef Narouz,
  • Doaa A Elmarzouky,
  • Amira A. Albawri,
  • Yara M. Harash,
  • Ahmed M. Zaghloul,
  • Alaa E. Ali,
  • Manar A. Balouz,
  • Ahmed Abdelgayed M. Hussein,
  • Fatma S. Mohamed,
  • Mohammed A. Alaeb,
  • Mohammed Ahmed Abdelrehim Mohammed

摘要

Chronic hand eczema (CHE) is a prevalent inflammatory skin condition affecting the hands, characterized by eczematous lesions, causing severe itching and discomfort. Drugs targeting the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway have emerged as new potential treatment for CHE. In this systematic review and meta-analysis, we aimed to assess the efficacy and safety of delgocitinib in CHE patients. We conducted a comprehensive search across available electronic databases to identify eligible studies reported up to January 2025. Outcomes were reported as risk ratios (RR), mean difference (MD), and confidence intervals (CIs), using RevMan 5.4. A P-value ≤ 0.05 is considered statistically significant. Three studies reporting on 1062 patients were included. The pooled analysis of the Hand Eczema Severity Index (HECSI) Score at Week 16 showed a significantly greater reduction in the delgocitinib 20 mg/g group (MD= − 39.65; 95% CI: − 47.22 to − 32.08; I² = 14%). There was no significant difference in overall adverse events between the groups. The discontinuation rate due to adverse events was lower in patients in the delgocitinib group. Delgocitinib significantly improved the CHE status, with no notable incidence of adverse events. Futures trials are recommended, including a wider population and longer follow-up durations.